A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.

E SöreskogF BorgströmIngrid LindbergO StrömD WillemsC LibanatiJ A KanisB StollenwerkM Charokopou

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)

Incorporating imminent fracture risk in economic evaluations has a significant impact on the cost-effectiveness when evaluating fracture prevention treatments in patients with osteoporosis who sustained a recent fracture. Bone-forming treatment followed by antiresorptive therapy can be cost-effective compared to antiresorptive therapy alone depending on treatment acquisition costs.

Keyphrases

bone mineral density
postmenopausal women
stem cells
hip fracture
soft tissue
body composition
bone loss
bone marrow
cell therapy